PDCD1 and cancer: Multiple studies showed that high mutation number of ctDNA was associated with improved OS and poor prognosis in patients with different cancer types treated with ICIs [105, 106]; Lee et al. [107] demonstrated that melanoma patients with persistently elevated ctDNA during PD-1 antibody therapy showed worse response and shorter PFS and OS.